Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943
Phase 1 trial enrolling patients with relapsed/refractory AML, MDS and B-cell ALLPALO ALTO, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) --...
Cancer
CancerVAX CEO Ryan Davies Discusses the Company’s Growing Pipeline of Cancer Treatments
The Company’s development pipeline now includes three projects with UCLALEHI, Utah, Sept. 14, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., a...
Intravacc Announces Review Publication of OMV-based Intranasal Vaccines for Disease Prevention
Intravacc - intranasally administered OMV Key mode of action of intranasally administered OMVs. Mucosal route induces both localized and systemic...
Sequana Medical announces H1 2023 results and provides business update
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION14 September 2023, 07:00 CEST alfapump® – strong pivotal POSEIDON data presented at leading international...
Pharmazz Inc. and Sun Pharma enter into licensing agreement for introducing Tyvalzi™ (Sovateltide) in India
Sovateltide is a first of its kind drug to treat acute cerebral ischemic stroke that can be administered up to...
Champions Oncology Reports Quarterly Revenue of $12.6 Million
HACKENSACK, NJ / ACCESSWIRE / September 13, 2023 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is...
Sarah Bush Lincoln Adopts DoseMe Precision Dosing Platform to Improve Overall Level of Patient Care
Hospital transitions to AUC-based dosing to achieve a comprehensive view of patient course of therapy, renal function, and overall population...
Patent Issued in Japan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
New patent issued to Napo Pharmaceuticals, a Jaguar Health family company, for core rare disease target indication for crofelemerJaguar is...
Cosmos Health Starts Stock Buyback Program
CHICAGO, IL / ACCESSWIRE / September 13, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...
Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease
Company's flu vaccine, mRNA-1010, met its primary endpoint in Phase 3 trial; separate Phase 1/2 data demonstrated higher HAI titers...
HOOKIPA Announces Executive Leadership Change
NEW YORK and VIENNA, Sept. 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a...
Association Sheds Light on Latest Advances of AHCC During Sexual Health Month
AHCC Impact on HPV Two studies published in the Frontiers in Oncology journal have showcased the potential of AHCC supplementation...
IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET
Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 13, 2023 (GLOBE...
Artelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20th
SOLANA BEACH, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling...
Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023
OXFORD, United Kingdom, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the...
Congenica and myTomorrows Announce Partnership to Advance Precision Oncology by Facilitating Rapid Access to Clinical Trials
AMSTERDAM and NEW YORK, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Congenica, a leading digital health company specializing in the provision...
PDS Biotech to Host Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 on September 27, 2023
Company to provide updated VERSATILE-002 data on combination of PDS0101 and KEYTRUDA®PRINCETON, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- PDS...
Adaptive Announces Launch of Epic Integration for clonoSEQ®
The Adaptive-Epic integration will provide clinicians and patients with easier access to minimal residual disease (MRD) monitoring in blood cancersSEATTLE,...
Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference
BOSTON, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the...
iSpecimen Expands Provider Network to Enhance Support for Women’s Health Research
Additional Providers Increase Biospecimen Access for Researchers Focused on Cervical, Uterine and Breast Cancers, as well as Reproductive Health, Cardiovascular...